Fridén BE - Search Results

1

Cell characteristics and function of two enriched fraction of human luteal cells prolonged culture.

Fridén BE, Hagström H, Lindblom B, Sjöblom P, Wallin A, Brännström M, Hahlin M. Fridén BE, et al. Mol Hum Reprod. 1999 Aug;5(8):714-9. doi: 10.1093/molehr/5.8.714. Mol Hum Reprod. 1999. PMID: 10421797

2

Phase-dependent influence of nonsteroidogenic cells on steroidogenesis and prostaglandin production by the human corpus luteum.

Fridén BE, Wallin A, Brännström M. Fridén BE, et al. Fertil Steril. 2000 Feb;73(2):359-65. doi: 10.1016/s0015-0282(99)00536-1. Fertil Steril. 2000. PMID: 10685544 Free article.

3

Evidence for nitric oxide acting as a luteolytic factor in the human corpus luteum.

Fridén BE, Runesson E, Hahlin M, Brännström M. Fridén BE, et al. Mol Hum Reprod. 2000 May;6(5):397-403. doi: 10.1093/molehr/6.5.397. Mol Hum Reprod. 2000. PMID: 10775642

4

Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study.

Pall M, Fridén BE, Brännström M. Pall M, et al. Among authors: friden be. Hum Reprod. 2001 Jul;16(7):1323-8. doi: 10.1093/humrep/16.7.1323. Hum Reprod. 2001. PMID: 11425807 Clinical Trial.

5

Immune regulation of corpus luteum function.

Brännström M, Fridén B. Brännström M, et al. Semin Reprod Endocrinol. 1997;15(4):363-70. doi: 10.1055/s-2008-1068374. Semin Reprod Endocrinol. 1997. PMID: 9580945 Review.

6

Extracellular matrix of the human cyclic corpus luteum.

Irving-Rodgers HF, Friden BE, Morris SE, Mason HD, Brannstrom M, Sekiguchi K, Sanzen N, Sorokin LM, Sado Y, Ninomiya Y, Rodgers RJ. Irving-Rodgers HF, et al. Among authors: friden be. Mol Hum Reprod. 2006 Sep;12(9):525-34. doi: 10.1093/molehr/gal060. Epub 2006 Jul 26. Mol Hum Reprod. 2006. PMID: 16870952

7

Variations in peripheral blood levels of immunoreactive tumor necrosis factor alpha (TNFalpha) throughout the menstrual cycle and secretion of TNFalpha from the human corpus luteum.

Brännström M, Fridén BE, Jasper M, Norman RJ. Brännström M, et al. Among authors: friden be. Eur J Obstet Gynecol Reprod Biol. 1999 Apr;83(2):213-7. doi: 10.1016/s0301-2115(99)00003-2. Eur J Obstet Gynecol Reprod Biol. 1999. PMID: 10391535

8

Using anti-Müllerian hormone to identify a good prognosis group in women of advanced reproductive age.

Fridén B, Sjöblom P, Menezes J. Fridén B, et al. Aust N Z J Obstet Gynaecol. 2011 Oct;51(5):411-5. doi: 10.1111/j.1479-828X.2011.01374.x. Aust N Z J Obstet Gynaecol. 2011. PMID: 21988118

9

Recombinant LH is equally effective as recombinant hCG in promoting oocyte maturation in a clinical in-vitro maturation programme: a randomized study.

Hreinsson J, Rosenlund B, Fridén B, Levkov L, Ek I, Suikkari AM, Hovatta O, Fridström M. Hreinsson J, et al. Hum Reprod. 2003 Oct;18(10):2131-6. doi: 10.1093/humrep/deg422. Hum Reprod. 2003. PMID: 14507834 Clinical Trial.

10

Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization.

Fridén BE, Nilsson L. Fridén BE, et al. Acta Obstet Gynecol Scand. 2005 Aug;84(8):812-6. doi: 10.1111/j.0001-6349.2005.00730.x. Acta Obstet Gynecol Scand. 2005. PMID: 16026411 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34 results

Search Page